Senior Commercial & Medical Excellence Manager, APAC
This role at Novo Nordisk involves leading commercial and medical execution strategy across the APAC region. You will bridge data insights with on-the-ground operational realities to improve field force effectiveness and customer engagement. The position requires strong analytics capabilities using Excel, Power BI, and CRM platforms like Veeva. You will partner with cross-functional leadership to drive strategic performance improvements.
50k new jobs listed every day. Install TAL to find more jobs like this.
Experience
8+ years
Function
Operations
Work mode
Onsite, Singapore
Company
Tier 2
What you will work on
This role at Novo Nordisk involves leading commercial and medical execution strategy across the APAC region. You will bridge data insights with on-the-ground operational realities to improve field force effectiveness and customer engagement. The position requires strong analytics capabilities using Excel, Power BI, and CRM platforms like Veeva. You will partner with cross-functional leadership to drive strategic performance improvements.
TAL's take
High-impact regional role at a major global pharmaceutical firm with clear strategic responsibilities.
Very well-defined responsibilities, clear regional scope, and specific technical requirements.
Salaries at Novo Nordisk
19.3 LPA average
Based on 19 Grapevine salary entries for Novo Nordisk.
Operations
4 - 6 years | L5
10 LPA average
Range: 10 - 10 LPA
Other roles
0 - 2 years
4 LPA average
Range: 4 - 4 LPA
Product Management
2 - 4 years | 6
14 LPA average
Range: 14 - 14 LPA
Other roles
2 - 4 years | 6
17 LPA average
Range: 17 - 17 LPA
Must haves
- 8+ years of experience in commercial excellence or business analytics
- Understanding of HCP customer engagement and field force execution
- Ability to translate complex customer data into actionable business recommendations
- Experience influencing senior stakeholders without formal authority
- Advanced Excel and dashboarding skills
- Experience with Veeva CRM or similar platforms
- Singaporean Citizenship or Permanent Residency
Tools and skills
About the company
Major global pharmaceutical corporation, highly reputable but not within the tech-specific Tier 1 definitions.
Posts mentioning Novo Nordisk
Amgen's Weight-Loss Drug Falls Short, Stock Plummets
- Amgen's MariTide Phase-2 data showed 20% weight loss at 52 weeks, but stock dropped 13.31% pre-market. - Rival stocks Eli Lilly and Novo Nordisk rose on Biden's proposal for expanded Medicare, Medicaid coverage for obesity drugs. - Retail investors remain bullish on Amgen despite analyst disappointment. Source: [Asianet Newsable](https://newsable.asianetnews.com/markets/amgen-stock-sinks-on-modest-obesity-drug-results-but-retail-sentiment-remains-steady-snk9xh), [Asianet Newsable](https://newsable.asianetnews.com/markets/eli-lilly-novo-nordisk-shares-climb-premarket-as-biden-administration-mulls-medicare-medicaid-covering-for-obesity-drugs-retail-unmoved-snk72g)
The Controversial Rise of Weight Loss Drugs
- Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs. - These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger. - The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug. - Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars. - However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic. - Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly. Source: [Modern MBA](https://www.youtube.com/watch?v=7sUoZVke_30&ab_channel=ModernMBA)
The Looming Fiscal Crisis Over Revolutionary Weight Loss Drugs
- America faces a fiscal crisis over revolutionary weight loss drugs like Ozempic and Wegovy. - These drugs, produced by Novo Nordisk, have potential cardiovascular, mental health, and anti-cancer benefits. - However, their high cost in the U.S. compared to other countries could bankrupt Medicare. - If half of U.S. adults with obesity took these drugs, it would cost $411 billion annually. - The State Treasurer of North Carolina, Dale Folwell, is questioning the high cost and has asked the federal government to negotiate with Novo Nordisk to open up patents to generic manufacturers. Source: [More Perfect Union](https://youtu.be/JqHmvMjXuro)